GlaxoSmithKline said to be eyeing sale of sports nutrition business

British drugs giant GlaxoSmithKline is said to be looking to divest its MaxiNutrition business, according to Reuters.

It is said that new CEO Emma Walmsley is on the brink of reshuffling the brand portfolio, with the sports nutrition business, bought only in 2010 for £162/$205 million, up for grabs.

Walmsley has been on board with GSK since April 1st.

If sold, this would represent a departure from sports nutrition for GSK, which also sold the Lucozade label in 2013 for £1.35 billion to Japan’s Suntory.

Further indications detailing the future of the portfolio will likely come to fruition in next month’s half-year financials. It is believed that Walmsley is keen to priorities GSK’s prescription drugs trade over off shoot brands.